Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 4/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.42 |
| ▸ | PRKACA | P17612 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.40 |
| ▸ | OGFRL1 | Q5TC84 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13071424 | 0.87 | TP53 (0.60) | TP53RPS6KB1ROCK1PRKACAGSK3B | |
| SCHEMBL9876669 | 0.83 | TP53 (0.46) | TP53CYP11B2BRD4RPS6KB1ROCK1 | |
| SCHEMBL4919026 | 0.77 | OPRM1 (0.44) | TP53CYP11B2RPS6KB1ROCK1OPRM1 | |
| SCHEMBL4917592 | 0.75 | HDAC3 (0.56) | TP53OGFRL1HDAC3HDAC1HDAC10 | |
| SCHEMBL4915657 | 0.72 | OGFRL1 (0.43) | TP53OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL4909486 | 0.72 | CYP1A2 (0.51) | TP53OPRM1OPRD1OPRK1OGFRL1 | |
| SCHEMBL9673866 | 0.69 | CCR5 (0.60) | TP53CYP11B2RPS6KB1ROCK1LMNA | |
| SCHEMBL29406440 | 0.69 | CYP11B2 (0.51) | TP53CYP11B2RPS6KB1ROCK1PRKACA | |
| SCHEMBL22612126 | 0.69 | CYP11B2 (0.51) | TP53CYP11B2RPS6KB1ROCK1PRKACA | |
| SCHEMBL2635863 | 0.69 | SMN1; SMN2 (0.53) | TP53CYP11B2RPS6KB1ROCK1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| CN-106459021-B | Compositions and methods for treating neurodegenerative diseases | 阿泽范药品公司 | 2023-04-07 | — | — | CN | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS INC (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200102294-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| US-10364236-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | AZEVAN PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20080113959-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AZEVAN PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080090797-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AZEVAN PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080033165-A1 | [Beta]-Lactamyl Vasopressin V1a Antagonists and Methods of Use | KOPPEL GARY A | 2008-02-07 | — | — | US | disclosed |
| WO-2007109615-A2 | β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS | AZEVAN PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109098-A2 | HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS | AZEVAN PHARMACEUTICALS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-7268125-B2 | β-lactamyl vasopressin V1a antagonists | AZEVAN PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20060281728-A1 | 3-Substituted beta-lactamyl vasopressin v1a antagonists | AZEVAN PHARMACEUTICALS, INC. | 2006-12-14 | — | — | US | disclosed |
| US-7119083-B2 | β-Lactamyl vasopressin V1a Antagonists | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | TP53 3579/4885CYP11B2 2250/4885BRD4 2112/4885 |
| US-20200102294-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | TP53 2365/4885CYP11B2 1404/4885BRD4 2456/4885 |
| US-20080090797-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AVPR1A, AVPR2, AVPR1B | TP53 4812/4885CYP11B2 1494/4885BRD4 3364/4885 |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | AVPR1A, AVPR2, AVPR1B | TP53 3882/4885CYP11B2 1228/4885BRD4 2893/4885 |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | GPX4, CRH, TXN | TP53 4873/4885CYP11B2 2492/4885BRD4 2630/4885 |
| US-20060281728-A1 | 3-Substituted beta-lactamyl vasopressin v1a antagonists | AVPR1A, AVPR2, AVPR1B | TP53 4058/4885CYP11B2 837/4885BRD4 2136/4885 |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | TP53 3579/4885CYP11B2 2250/4885BRD4 2112/4885 |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | GABBR1, GABBR2, ALAD | TP53 4832/4885CYP11B2 433/4885BRD4 4380/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | TP53 2365/4885CYP11B2 1404/4885BRD4 2456/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | TP53 2365/4885CYP11B2 1404/4885BRD4 2456/4885 |
| US-20080113959-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AVPR1A, AVPR2, AVPR1B | TP53 4812/4885CYP11B2 1494/4885BRD4 3364/4885 |
| US-10364236-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | TP53 2365/4885CYP11B2 1404/4885BRD4 2456/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | TP53 3579/4885CYP11B2 2250/4885BRD4 2112/4885 |
| US-20080033165-A1 | [Beta]-Lactamyl Vasopressin V1a Antagonists and Methods of Use | AVPR2, AVPR1A, AVPR1B | TP53 4107/4885CYP11B2 1398/4885BRD4 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.